According to the Zhitong Finance App, Hanson Pharmaceuticals (03692.HK) announced that HS-10582 tablets, a Class 1 new drug independently developed by the Group, have received a drug clinical trial approval notice issued by the China National Drug Administration (NMPA) to carry out clinical trials for “treating adult-induced hypercholesterolemia and mixed dyslipidemia”.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.